Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome

Br J Haematol. 2018 Jul;182(2):200-211. doi: 10.1111/bjh.15390. Epub 2018 Jun 19.
No abstract available

Keywords: down syndrome; neonatal leukaemia; transient abnormal myelopoiesis; transient leukaemia; transient myeloproliferative disorder.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Blood Cell Count
  • Cell Transformation, Neoplastic
  • Critical Illness
  • Cytarabine / therapeutic use
  • DNA Mutational Analysis / methods
  • Down Syndrome / pathology
  • Down Syndrome / therapy*
  • Exchange Transfusion, Whole Blood / methods
  • Female
  • Fetal Diseases / diagnosis
  • GATA1 Transcription Factor / genetics
  • Humans
  • Leukapheresis / methods
  • Leukemoid Reaction / pathology
  • Leukemoid Reaction / therapy*
  • Liver Diseases / therapy
  • Mutation / genetics
  • Neoplasm, Residual / diagnosis
  • Pregnancy
  • Prenatal Diagnosis / methods
  • Prognosis
  • Recurrence
  • Risk Factors

Substances

  • Antimetabolites, Antineoplastic
  • GATA1 Transcription Factor
  • GATA1 protein, human
  • Cytarabine

Supplementary concepts

  • Myeloproliferative Syndrome, Transient